XORTX Therapeutics (NASDAQ:XRTX) Releases Quarterly Earnings Results

XORTX Therapeutics (NASDAQ:XRTX) issued its quarterly earnings data on Friday. The technology company reported ($0.21) earnings per share (EPS) for the quarter, FiscalAI reports.

XORTX Therapeutics Price Performance

Shares of XRTX traded up $0.18 during mid-day trading on Friday, hitting $1.10. 1,586,112 shares of the company’s stock were exchanged, compared to its average volume of 71,803. XORTX Therapeutics has a 52 week low of $0.82 and a 52 week high of $3.60. The company has a market cap of $2.00 million, a PE ratio of -0.40 and a beta of 0.83. The company has a 50-day simple moving average of $1.47 and a 200 day simple moving average of $2.03.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of XORTX Therapeutics in a research note on Monday, September 21st. One investment analyst has rated the stock with a Sell rating. According to MarketBeat, the stock has a consensus rating of “Sell”.

XORTX Therapeutics Company Profile

XORTX Therapeutics Inc. (NASDAQ:XRTX) is a clinical-stage pharmaceutical company focused on developing therapies for conditions associated with dysregulated uric acid metabolism. The company’s research is centered on inhibiting xanthine oxidase, an enzyme involved in uric acid production, with the goal of addressing kidney and other serious chronic diseases. XORTX’s development programs include XRx-008, an orally administered therapy being developed for autosomal dominant polycystic kidney disease, a genetic disorder that can progressively impair kidney function.